Other pathways, induced by cisplatin and the ARF tumor suppressor, do not appear to affect NF-κB nuclear localization but rather modulate the activity of NF-κB, resulting in a more selective repression of NF-κB target genes [8]. Here, CDKN2A is linked to neoplasm.